- Home
- CSTL vs SLRC Comparison
CSTL vs SLRC Comparison
Compare CSTL & SLRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- SLRC
- Stock Information
- Founded
- CSTL 2007
- SLRC 2007
- Country
- CSTL United States
- SLRC United States
- Employees
- CSTL N/A
- SLRC N/A
- Industry
- CSTL Medical Specialities
- SLRC Finance/Investors Services
- Sector
- CSTL Health Care
- SLRC Finance
- Exchange
- CSTL Nasdaq
- SLRC Nasdaq
- Market Cap
- CSTL 848.1M
- SLRC 885.4M
- IPO Year
- CSTL 2019
- SLRC 2010
- Fundamental
- Price
- CSTL $27.14
- SLRC $16.33
- Analyst Decision
- CSTL Strong Buy
- SLRC Sell
- Analyst Count
- CSTL 6
- SLRC 4
- Target Price
- CSTL $39.67
- SLRC $15.25
- AVG Volume (30 Days)
- CSTL 301.1K
- SLRC 173.4K
- Earning Date
- CSTL 11-04-2024
- SLRC 11-06-2024
- Dividend Yield
- CSTL N/A
- SLRC 10.11%
- EPS Growth
- CSTL N/A
- SLRC 34.99
- EPS
- CSTL 0.21
- SLRC 1.77
- Revenue
- CSTL $311,878,000.00
- SLRC $236,635,000.00
- Revenue This Year
- CSTL $51.36
- SLRC $4.11
- Revenue Next Year
- CSTL N/A
- SLRC N/A
- P/E Ratio
- CSTL $131.77
- SLRC $9.15
- Revenue Growth
- CSTL 62.43
- SLRC 5.79
- 52 Week Low
- CSTL $16.97
- SLRC $14.41
- 52 Week High
- CSTL $35.84
- SLRC $16.91
- Technical
- Relative Strength Index (RSI)
- CSTL 39.78
- SLRC 49.80
- Support Level
- CSTL $26.99
- SLRC $15.79
- Resistance Level
- CSTL $28.08
- SLRC $16.21
- Average True Range (ATR)
- CSTL 1.51
- SLRC 0.23
- MACD
- CSTL -0.15
- SLRC -0.07
- Stochastic Oscillator
- CSTL 22.78
- SLRC 42.41
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.
About SLRC SLR Investment Corp.
SLR Investment Corp is a closed-end externally managed, non-diversified management investment company that has elected to be treated as a business development company. It provides U.S. middle market businesses and intermediaries with bespoke debt financing solutions to fund working capital, acquisition, refinancing and growth capital requirements. It invests majorly in leveraged middle-market companies in the form of senior secured loans, financing leases and to a lesser extent, unsecured loans and equity securities.